News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Consumers Now Use Medical Cost Websites to Price Shop for Clinical Pathology Laboratory Tests and Other Medical Procedures

Price transparency expected to encourage competition among healthcare providers, including medical laboratories

Before consumers visit a clinical laboratory, they can now check the “fair” price of medical laboratory tests. New websites have sprung up that make it easy for consumers to find what experts consider to be fair market prices for each type of lab test, as well as for other medical procedures and healthcare services.

Pathologists should think of the well-known “Kelly Blue Book” that has been the price authority for prices of new and used automobiles for decades. These new medical price websites are easy to use and make it quick for a consumer to find “fair” prices for common clinical laboratory test and medical procedure.

These new web-based companies are organized to serve the needs of consumers who are enrolled in high-deductible health plans (HDHP). For an individual, an annual deductible can be as high as $2,500—and as much as $5,000 for a family. Thus, clinical laboratory managers should not be surprised that consumers are actively price-shopping before they visit their laboratory to have a specimen collected.
(more…)

Humana and Norton Healthcare’s Pilot ACO Triggered Both Increased Utilization of Clinical Laboratory Tests and Improved Patient Outcomes

Clinical laboratory managers and pathologists will want to develop strategies for adding value under ACO model

One lesson learned from a pilot accountable care organization (ACO) project is that increased utilization of clinical laboratory testing in appropriate circumstances will contribute to improved patient outcomes. Just one year into a pilot ACO partnership, Norton Healthcare and insurer Humana Inc. (NYSE: HUM) have shown quality gains and some modest savings.

This is encouraging news for pathologists and clinical laboratory managers. It shows that, when physicians participating in ACOs more closely follow evidence-based medicine (EBM) guidelines, the increase in lab test utilization can play the expected role in improving diagnosis and guiding therapeutic choices. However, it should be noted that the results disclosed by the Norton/Humana ACO pilot only cover a short period of time. (more…)

;